Cost-effectiveness analysis of recombinant activated factor VII as adjunctive therapy for bleeding control in severely injured trauma patients in Germany

Ejemplares similares

• Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
  por: Rizoli, Sandro B, et al.
  Publicado: (2006)
• Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
  por: Klitgaard, Thomas, et al.
  Publicado: (2006)
• A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
  por: Rossaint, R, et al.
  Publicado: (2005)
• Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
  por: Vincent, Jean-Louis, et al.
  Publicado: (2006)
• Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
  por: Kluger, Yoram, et al.
  Publicado: (2007)